Deep proteome profiling of over 5,000 cerebrospinal fluid samples by mass spectrometry maps protein alterations across major neurological disorders, resolving key sources of variation as well as shared and disease-specific signatures. This framework yields a 22-protein assay that improves the differential diagnosis of multiple sclerosis from other inflammatory conditions, particularly in diagnostically challenging oligoclonal band-negative individuals.